Nordson Introduces Encore® Engage Powder Coating Controller at FABTECH
11.11.2019 08:05:00 EET | Business Wire | Press release
Nordson Industrial Coating System, a Nordson company (NASDAQ: NDSN) and leading supplier of equipment for the precise application of industrial coating solutions, introduces Encore® Engage, its newest powder coating controller. This next-generation of Nordson powder coating controller technology promises to deliver effortless, intuitive control for increased efficiency and maximum productivity.
Encore Engage provides customers clarity and confidence in every step of the powder coating process. “From the very start, we designed Encore Engage with powder coaters in mind, building in customer feedback and making user experience our top priority,” says Stephen Lovass, Executive Vice President, Nordson Industrial Coatings Systems.
Featuring an easy-to-understand, 15-inch touchscreen with modern graphics and intuitive symbol-driven navigation, Encore Engage helps operators increase process knowledge and become expert powder coaters. In addition, a guided recipe feature provides step-by-step navigation with preset options to help operators confidently create new recipes. Video tutorials and guided instructions provide greater visibility to key information and give additional support for critical tasks. For operators around the world, Encore Engage includes several screen language options to eliminate guesswork and uncertainty.
Nordson has a 65-year history of innovating to help customers become more competitive and produce better products. Encore Engage is one more example of that innovation, connecting to the Nordson Wisdom™ smart connected platform, an IIoT solution that brings powder coating customers into the era of Industry 4.0. Encore Engage and the Wisdom smart connected platform combine Nordson’s proven hardware, controls, application expertise and field support to help customers improve their manufacturing process.
Lovass remarks, “Our Encore Engage controller empowers powder coating operators to become experts in what they do. We set out to give powder coaters not just a controller they can enjoy using, but also a tool that makes them feel confident in how they do their work.”
For more information about the Encore Engage powder application controller, visit www.nordsoncoating.com/engage.
Encore Engage demonstration at FABTECH 2019, booth B13018
About Nordson Industrial Coating Systems
Nordson Industrial Coating Systems (ICS) designs and manufactures precision equipment for the application and curing of powders, paints, liquids, adhesives and sealants. ICS has lab and manufacturing facilities in North America, Europe and Asia to support our global customer base across a broad range of markets including automotive, aerospace, electronics, agriculture and construction, appliance, furniture, beverage and other industrial markets. Nordson ICS, Performance by Design. To find out more, visit www.nordson.com/industrial-coating-systems.
About Nordson Corporation
Nordson Corporation (Nasdaq: NDSN) engineers, manufactures, and markets differentiated products and systems used for the precision dispensing and processing of adhesives, coatings, polymers and plastics, sealants, biomaterials, and other materials and for fluid management, test and inspection, UV curing , and plasma surface treatment, all supported by application expertise and direct global sales and service. Nordson serves a wide variety of consumer non-durable, durable, and technology end markets including packaging, nonwovens, electronics, medical, appliances, energy, transportation, construction, and general product assembly and finishing. Founded in 1954 and headquartered in Westlake, Ohio, the company has operations and support offices in more than 30 countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191110005055/en/
Contact information
Christina Mahlenkamp
+1.440.414.5186
Christina.Mahlenkamp@nordson.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom